An Aminoglycoside-Sparing Regimen with Double Beta-Lactam to Successfully Treat Granulicatella adiacens Prosthetic Aortic Valve Endocarditis-Time to Change Paradigm?
(1) Background: Granulicatella adiacens is a former nutritionally variant streptococci (NVS). NVS infective endocarditis (IE) is generally characterized by a higher rate of morbidity and mortality, partially due to difficulties in choosing the most adequate microbiological culture method and the most effective treatment strategy, and partially due to higher rates of complications, such as heart failure, peripheral septic embolism, and peri-valvular abscess, as well as a higher rate of valve replacement. Depending on the affected valve (native valve endocarditisNVE, or prosthetic valve endocarditisPVE), the American Heart Association (AHA) 2015 treatment guidelines (GLs) suggest penicillin G, ampicillin, or ceftriaxone plus gentamicin (2 weeks for NVE and up to 6 weeks for PVE), while vancomycin alone may be a reasonable alternative in patients who are intolerant of β-lactam therapy. The European Society of Cardiology (ESC) 2023 GLs recommend treating NVE with penicillin G, ceftriaxone, or vancomycin for 6 weeks, suggesting combined with an aminoglycoside (AG) for at least the first 2 weeks only for PVE; likewise, the same recommendations for IE due to Enterococcus faecalis. (2) Methods: Starting from the case of a 51-year-old man with G. adiacens aortic bio-prosthesis IE who was successfully treated with aortic valve replacement combined with double beta-lactams, an AG-sparing regimen, we performed microbiology tests in order to validate this potential treatment change. (3) Results: As for E. faecalis IE, we found that the combination of ampicillin plus cephalosporines (like ceftriaxone or ceftobiprole) showed a synergistic effect in vitro, probably due to wider binding to penicillin-binding proteins (PBPs), thus contributing to enhanced bacterial killing and good clinical outcome, as well as avoiding the risk of nephrotoxicity due to AG association therapy. (4) Conclusions: Further studies are required to confirm this hypothesis, but double beta-lactams and an adequate sourcecontrol could be a choice in treating G. adiacens IE.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Infectious disease reports - 16(2024), 2 vom: 14. März, Seite 249-259 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pagotto, Alberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibiotics |
|---|
| Anmerkungen: |
Date Revised 27.03.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/idr16020020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370153367 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370153367 | ||
| 003 | DE-627 | ||
| 005 | 20240328000330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240326s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/idr16020020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM370153367 | ||
| 035 | |a (NLM)38525767 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pagotto, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Aminoglycoside-Sparing Regimen with Double Beta-Lactam to Successfully Treat Granulicatella adiacens Prosthetic Aortic Valve Endocarditis-Time to Change Paradigm? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a (1) Background: Granulicatella adiacens is a former nutritionally variant streptococci (NVS). NVS infective endocarditis (IE) is generally characterized by a higher rate of morbidity and mortality, partially due to difficulties in choosing the most adequate microbiological culture method and the most effective treatment strategy, and partially due to higher rates of complications, such as heart failure, peripheral septic embolism, and peri-valvular abscess, as well as a higher rate of valve replacement. Depending on the affected valve (native valve endocarditisNVE, or prosthetic valve endocarditisPVE), the American Heart Association (AHA) 2015 treatment guidelines (GLs) suggest penicillin G, ampicillin, or ceftriaxone plus gentamicin (2 weeks for NVE and up to 6 weeks for PVE), while vancomycin alone may be a reasonable alternative in patients who are intolerant of β-lactam therapy. The European Society of Cardiology (ESC) 2023 GLs recommend treating NVE with penicillin G, ceftriaxone, or vancomycin for 6 weeks, suggesting combined with an aminoglycoside (AG) for at least the first 2 weeks only for PVE; likewise, the same recommendations for IE due to Enterococcus faecalis. (2) Methods: Starting from the case of a 51-year-old man with G. adiacens aortic bio-prosthesis IE who was successfully treated with aortic valve replacement combined with double beta-lactams, an AG-sparing regimen, we performed microbiology tests in order to validate this potential treatment change. (3) Results: As for E. faecalis IE, we found that the combination of ampicillin plus cephalosporines (like ceftriaxone or ceftobiprole) showed a synergistic effect in vitro, probably due to wider binding to penicillin-binding proteins (PBPs), thus contributing to enhanced bacterial killing and good clinical outcome, as well as avoiding the risk of nephrotoxicity due to AG association therapy. (4) Conclusions: Further studies are required to confirm this hypothesis, but double beta-lactams and an adequate sourcecontrol could be a choice in treating G. adiacens IE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Granulicatella spp. | |
| 650 | 4 | |a antibiotics | |
| 650 | 4 | |a betalactams | |
| 650 | 4 | |a infective endocarditis | |
| 650 | 4 | |a nutritionally variant streptococci | |
| 650 | 4 | |a penicillin-binding proteins | |
| 700 | 1 | |a Campanile, Floriana |e verfasserin |4 aut | |
| 700 | 1 | |a Conti, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Prataviera, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Della Siega, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Flammini, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Giuliano, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Martini, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Pecori, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Sartor, Assunta |e verfasserin |4 aut | |
| 700 | 1 | |a Screm, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Semenzin, Tosca |e verfasserin |4 aut | |
| 700 | 1 | |a Tascini, Carlo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious disease reports |d 2009 |g 16(2024), 2 vom: 14. März, Seite 249-259 |w (DE-627)NLM206505906 |x 2036-7430 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:2 |g day:14 |g month:03 |g pages:249-259 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/idr16020020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 2 |b 14 |c 03 |h 249-259 | ||